Graft Versus Host Disease (GVHD)

**Prevention**
- **BMT304**
  - Phase II Obinutuzumab in Prevention of cGVHD After Allogeneic Peripheral Blood Stem Cell Transplant
  - PI: Miklos Dana, Farber

- **BMT329**
  - Phase II Defibrotide Added vs SoC Immunophrophylaxis in Prevention of aGVHD After Allogeneic HSCT
  - PI: Arai Pending

**Chronic**
- **VAR0158**
  - Phase I Pirfenidone for Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation
  - PI: Hsu Stanford

- **BMT350**
  - Phase II KD025 in Chronic Graft Versus Host Disease After 2 Prior Lines of Systemic Therapy
  - PI: Arai Pending

**New Onset**
- **BMT311**
  - Phase III Ibrutinib Combo w/ Corticosteroids vs Placebo Combo w/ Corticosteroids in New Onset cGVHD
  - PI: Miklos Pharmacylcs

- **BMT327**
  - Phase II Ibrutinib or Placebo +/- Corticosteroids in First-Line Acute Graft-Versus-Host Disease Tx
  - PI: Meyer Incyte Corporation

- **BMT267**
  - Phase I Primary T Regulatory Cell Tx to Treat Visceral Acute GVHD After HCT
  - PI: Meyer Stanford

**Acute**
- **BMT322**
  - Detection of GVHD w/ [18F]-Da-G, a Positron Emission Tomography Tracer for Activated T Cells
  - PI: Gambhir Stanford

**Diagnostic**
- Within 3 days of Steroid Treatment

---

**KEY**
- Pending
- Open for Enrollment
- Observation Study
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy

*Please mark up a copy using black ink and email changes to SRC-office@stanford.edu*